Dexamethasone is a generic drug that’s prescribed for treating many conditions, including multiple sclerosis and allergic reactions. As with other drugs, dexamethasone can cause side effects ...

Treatment with fixed-dose subcutaneous Sarclisa plus Pomalyst and dexamethasone was non-inferior to IV Sarclisa in ...

Sanofi's Sarclisa SC formulation shows non-inferiority versus Sarclisa IV infusion in a late-stage study for treating ...

Dexamethasone sodium phosphate is under clinical development by AVM Biotechnology and currently in Phase II for Unspecified B-Cell Lymphomas.

Dexamethasone sodium phosphate is under clinical development by AVM Biotechnology and currently in Phase II for Metastatic Pancreatic Cancer.

During a Case-Based Roundtable® event, Rahul Banerjee, MD, discussed approaches to dosing and tolerability when using ...

Sanofi SA (NASDAQ:SNY) released results from the IRAKLIA phase 3 study evaluating the non-inferiority of Sarclisa (isatuximab ...

China NMPA approves Sanofi’s Sarclisa in combo with pomalidomide and dexamethasone to treat adult patients with R/R multiple myeloma: Paris Tuesday, January 14, 2025, 10:00 Hrs ...

C4 Therapeutics (CCCC) announced its anticipated 2025 milestones as it continues its evolution into becoming a fully integrated biotechnology ...

French drug major Sanofi (SNY) announced Monday that its Sarclisa has obtained first approval in China for the treatment of adult ...

Dexamethasone provided 4 mg at every 6 hours, the usual initial dose—equivalent to 400 mg of cortisol per day—is about 20 times the normal rate of endogenous production. In patients who have ...

CT-guided infiltration treatment was well tolerated and was associated with virtually no side effects in this study. Conclusion: CT-guided infiltration of dexamethasone palmitate, particularly in ...